Tokyo, April 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061150) titled 'Atopic Dermatitis - Treatment Response EVALuation and UsEr Satisfaction with Tralokinumab in Standard Clinical Practice in Japan' on April 8.
Study Type:
Observational
Primary Sponsor:
Institute - LEO Pharma K.K.
Condition:
Condition - atopic dermatitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This observational study aims to assess the 52-week real-world effectiveness, safety, and patient-reported outcomes of tralokinumab. Furthermore, the data will be integrated with international studies to characterize the global clinical profile of the treatment.
Basic...